Mastering the complexities of targeted medicines
White paper
Download now
This white paper presents considerations for planning, developing, and bringing to market targeted medicines with specific considerations for organizations to contemplate across key domains.
Key learning objectives:
- Understanding the regulatory landscape for targeted medicines
- Learning how biomarkers are used in treatment with a targeted therapy
- Discovering why companion diagnostics (CDx) are an indispensable tool in the field of targeted therapies
- Developing strategies to navigate the complexities of developing targeted medicines
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.